Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RYZ101 + SoC in SSTR+ ES-SCLC
NCT05595460Phase 1Active, not recruiting
- Sponsor
- RayzeBio
- Start
- Oct 2022
- Primary completion
- Jul 2027
- Modality
- Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of actinium-225 dotatate in small cell lung cancer (SCLC), sponsored by RayzeBio. Primary endpoints: Recommended Phase 2 Dose at 42 days and Safety and tolerability up to 50 months. Started Oct 2022; status: active, not recruiting.
02
Drugs
actinium-225 dotatate
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05595460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05595460.